Results 31 to 40 of about 122,678 (147)

Neutralizing antibody titres in SARS-CoV-2 infections [PDF]

Nature Communications, 2021
AbstractThe SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 ...
Lau, Eric H. Y., Tsang, Owen T. Y., Hui, David S. C., Kwan, Mike Y. W., Chan, Wai-hung, Chiu, Susan S., Ko, Ronald L. W., Chan, Kin H., Cheng, Samuel M. S., Perera, Ranawaka A. P. M., Cowling, Benjamin J., Poon, Leo L. M., Peiris, Malik   +12 more
openaire   +3 more sources

Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA

BMC Veterinary Research, 2022
Background Little is known about the epidemic status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cats in Japan due to insufficiently reliable seroepidemiological analysis methods that are easy to use in cats. Results We developed a
Ichiro Imanishi, Ryota Asahina, Shunji Hayashi, Jumpei Uchiyama, Masaharu Hisasue, Masahiro Yamasaki, Yoshiteru Murata, Shigeru Morikawa, Tetsuya Mizutani, Masahiro Sakaguchi   +9 more
doaj   +1 more source

Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman

Journal of Infection and Public Health, 2021
Objectives: The primary objective is to determine the prevalence of SARS-CoV-2 antibodies persistence among HCWs and specifically among asymptomatic HCWs.
Khalid Al-Naamani, Issa Al-Jahdhami, Wafa Al-Tamtami, Kawther Al-Amri, Murtadha Al-Khabori, Siham Al Sinani, Elias A. Said, Heba Omer, Hamad Al-Bahluli, Saada Al-Ryiami, Saleh Al-Hakmani, Najat Al-Naamani, Ruqaiya Al-Jahwari, Musheera Al-Hinai, Juhaina AlWahaibi   +14 more
doaj   +1 more source

Neutralizing antibodies against SARS-CoV-2

Uirusu, 2023
Severe acute respiratory syndrome (SARS) corona virus 2 (SARS-CoV-2) is a novel coronavirus that infects humans and causes respiratory symptoms, resulting in a global pandemic since its appearance in 2019. Neutralizing antibody production is an important immune response following SARS-CoV-2 infection, and a great deal of research has been performed ...
openaire   +2 more sources

Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study

Microorganisms, 2021
While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes serious morbidity and mortality in humans (coronavirus disease 2019, COVID-19), there is an enormous range of disease outcomes following virus exposures.
Robert E. Sealy, Julia L. Hurwitz
doaj   +1 more source

Post-vaccination antibodies against SARS-CoV-2: Correspondence

Archivos de Prevención de Riesgos Laborales, 2022
Dear Editor, we would like to share ideas on the publication “Post-vaccination antibodies against SARS-CoV-2 in a cohort of workers of a general hospital”(1). In the cohort and with fresh SARS-CoV-2 infections, Sabater Vidal et al. noticed a general decrease in IgG-S and IgG-NP antibodies following the second dosage of the Pfizer-BioNTech vaccine (1 ...
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit   +1 more
openaire   +4 more sources

Neutralizing antibodies for SARS-CoV-2 infection

Revista Española de Quimioterapia, 2022
The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression.
openaire   +2 more sources

SARS-CoV-2 and Anti-Cardiolipin Antibodies

Clinical Medicine Insights: Case Reports, 2020
The current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to distinct diagnostic and management challenges for front-line healthcare workers. The risk of excessive coagulation activation leading to a cascade of thrombotic events in critically ill patients with SARS-CoV-2 is now well reported.
Mazen Jizzini, Mohsin Shah, Kehua Zhou
openaire   +4 more sources

Saliva SARS-CoV-2 Antibody Prevalence in Children

Microbiology Spectrum, 2021
Comprehending humoral immunity to SARS-CoV-2, including in children, is crucial for future public health and vaccine strategies. Others have suggested that mucosal antibody measurement could be an important and more convenient tool to evaluate humoral immunity compared to circulating antibodies.
Maya W. Keuning, Marloes Grobben, Anne-Elise C. de Groen, Eveline P. Berman-de Jong, Merijn W. Bijlsma, Sophie Cohen, Mariet Felderhof, Femke de Groof, Daniel Molanus, Nadia Oeij, Maarten Rijpert, Hetty W. M. van Eijk, Gerrit Koen, Karlijn van der Straten, Melissa Oomen, Remco Visser, Federica Linty, Maurice Steenhuis, Gestur Vidarsson, Theo Rispens, Frans B. Plötz, Marit J. van Gils, Dasja Pajkrt   +22 more
openaire   +3 more sources

Equine Hyperimmune Serum against the Inactivated SARS-CoV-2 Has Antibodies Neutralizing Titers [PDF]

Brazilian Archives of Biology and Technology
The use of passive immunization could be a strategy for the control of SARS-CoV-2 infections. Our study proposes to produce anti-SARS-CoV-2 antibodies from the immunization of horses, and purify F(ab’)2 fragment aiming to provide a therapy capable of ...
Neida Lucia Conrad, Vitória Sequeira Gonçalves Zorzi, Francisco Denis Souza Santos, César Graner, Marcelle Moura Silveira, Juliana Schons Gularte, Micheli Filippi, Karoline Schallenberger, Juliane Deise Fleck, Bruno Lopes Abbadi, Cristiano Valim Bizarro, Pablo Machado, Luiz Augusto Basso, Fabrício Rochedo Conceição, Carlos Eduardo Wayne Nogueira, Fernando Rosado Spilki, Fábio Pereira Leivas Leite   +16 more
doaj   +1 more source